Long-term Study of Epiduo in Patients With Moderate to Severe Acne

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This observational study is designed to assess the long-term efficacy and safety of Epiduo (alone or in combination with other drugs) under daily clinical practice conditions in patients with moderate to severe inflammatory acne. In addition, the effect of Epiduo on quality of life and patient adherence will be assessed under marketed conditions.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Galderma Laboratorium GmbH
• Treatments: Adapalene; Adapalene, Benzoyl Peroxide Drug Combination; Benzoyl Peroxide

Criteria

Inclusion Criteria:

• The patient has been diagnosed with moderate to severe inflammatory acne (Leeds Grade 4-12)

• Topical therapy of acne with Epiduo is indicated, the decision about treating the patient with Epiduo has been made independently from this study

Exclusion Criteria:

• Use of Epiduo within 3 months prior to inclusion

• Pregnancy or breastfeeding

• Acne inversa

• Acne with preferential manifestation of microcysts, macrocysts and macrocomedones

• Hypersensitivity to the drug or any of its ingredients

• If applicable, other restrictions outlined in the SPC of Epiduo